Add to ORKGBACKGROUND: Extended interval dosing (EID) of natalizumab treatment is increasingly used in multiple sclerosis. Besides the clear anti-inflammatory effect, natalizumab is considered to have neuroprotective properties as well. OBJECTIVES: This study aimed to study the longitudinal effects of EID compared to standard interval dosing (SID) and natalizumab drug concentrations on brain atrophy. METHODS: Patients receiving EID or SID of natalizumab with a minimum radiological follow-up of 2 years were included. Changes in brain atrophy measures over time were derived from clinical routine 3D-Fluid Attenuated Inversion Recovery (FLAIR)-weighted magnetic resonance imaging (MRI) scans using SynthSeg. RESULTS: We found no differences between EID (n =...
Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relap...
OBJECTIVE: To describe the effect of natalizumab in the treatment of subjects with active multiple s...
Extending the natalizumab interval after the 24th administration could reduce the risk of progressiv...
Background: Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatm...
The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced...
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by bindi...
BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with exten...
Background: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-po...
OBJECTIVE: To determine whether natalizumab efficacy is maintained when switching to personalized ex...
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple ...
BACKGROUND: Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-re...
Francesco Patti, Angelo PappalardoMultiple Sclerosis Center, University of Catania, Catania, Italy; ...
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. A...
The recommended natalizumab dosage is 300 mg every 4 weeks. We evaluated radiological activity at va...
Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relap...
OBJECTIVE: To describe the effect of natalizumab in the treatment of subjects with active multiple s...
Extending the natalizumab interval after the 24th administration could reduce the risk of progressiv...
Background: Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatm...
The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced...
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by bindi...
BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with exten...
Background: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-po...
OBJECTIVE: To determine whether natalizumab efficacy is maintained when switching to personalized ex...
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple ...
BACKGROUND: Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-re...
Francesco Patti, Angelo PappalardoMultiple Sclerosis Center, University of Catania, Catania, Italy; ...
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. A...
The recommended natalizumab dosage is 300 mg every 4 weeks. We evaluated radiological activity at va...
Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relap...
OBJECTIVE: To describe the effect of natalizumab in the treatment of subjects with active multiple s...
Extending the natalizumab interval after the 24th administration could reduce the risk of progressiv...